Business Context and Reporting Period
This Form 8-K is a current report filed by Lument Finance Trust, Inc. on July 24, 2026, regarding a notice received from the New York Stock Exchange (NYSE). The Company is a Maryland corporation with its principal executive offices in New York, New York. Its common stock (LFT) and 7.875% Series A Cumulative Redeemable Preferred Stock (LFTPrA) are listed on the NYSE.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The only financial metric disclosed is the average closing price of the Company's common stock, which was reported as less than $1.00 over a consecutive 30-trading-day period.
Material Changes
The material event reported is the receipt of a Notice of Deficiency from the NYSE under Section 802.01C of the Listed Company Manual. This notice indicates non-compliance with the minimum share price requirement. The filing clarifies that this is a notice of deficiency, not an immediate delisting, and trading of the Company's common stock continues on the NYSE.
Outlook, Management Commentary, and Risks
- Cure Period: The Company has a six-month cure period to regain compliance. Compliance can be achieved if, on the last trading day of any calendar month during this period, the closing share price is at least $1.00 and the 30-day average closing price is at least $1.00.
- Management Action: Management intends to monitor the market price and is considering all available alternatives to regain compliance, including a reverse stock split, subject to required corporate approvals.
- Commitment Status: The Company has not committed to any specific course of action at this time.
- Risks: The filing includes standard forward-looking statement disclaimers, noting that plans to regain compliance are subject to substantial risks and uncertainties beyond the Company's control.
Investor Verification Checklist
- Verify the current trading price of LFT common stock to assess proximity to the $1.00 threshold.
- Monitor upcoming shareholder meetings or proxy statements for votes on a potential reverse stock split.
- Review the Company's most recent Form 10-K (for the year ended December 31, 2025) for detailed risk factors related to delisting and liquidity.
- Track the Company's progress in meeting the 30-day average price requirement during the six-month cure period.